Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 110

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 110
---
 vary materially and
adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses
could prove to be significantly higher than we currently anticipate.

Our future capital requirements
will depend on many factors, including, but not limited to:

| ● | the progress and costs of our research and development activities; |

| ● | the costs of development and expansion of our operational infrastructure; |

| ● | our ability, or that of our collaborators, to achieve development milestones and other events or developments under potential future licensing agreements; |

| ● | the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements with respect to our technologies; |

| ● | the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; |

| ● | the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves, once our technologies are developed and ready for commercialization; |

| ● | the costs of acquiring or undertaking development and commercialization efforts for any future products or technology; |

| ● | the magnitude of our general and administrative expenses; and |

| ● | any additional costs that we may incur under future in- and out-licensing arrangements relating to our technologies and futures products. |

<div align='center'>67</div>

Until we can generate significant
recurring revenues, we expect to satisfy our future cash needs through capital raising or by out-licensing and/or co-developing applications
of one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if
at all. If funds are not available on favorable terms, or at all, we may be required to delay, reduce the scope of or eliminate research
or development efforts or plans for commercialization with respect to our technologies and make necessary change to our operations to
reduce the level of our expenditures in line with available resources.

We are a development-stage
technology company and it is not possible for us to predict with any degree of accuracy the outcome of our research and development efforts.
As such, it is not possible for us to predict with any degree of accuracy any significant trends, uncertainties, demands, commitments
or events that are reasonably likely to have a material effect on our net loss, liquidity or capital resources, or that would cause financial
information to not necessarily be indicative of future operating results or financial condition. However, to the extent possible